首页> 美国卫生研究院文献>Springer Open Choice >Kinetic studies of novel inhibitors of endomorphin degrading enzymes
【2h】

Kinetic studies of novel inhibitors of endomorphin degrading enzymes

机译:新型内啡肽降解酶抑制剂的动力学研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Endomorphins (EMs), two endogenous μ-opioid receptor selective ligands, are attractive lead compounds for opioid-based pain management studies. However, these peptides are quickly degraded by peptidases, in particular by dipeptidylpeptidase IV (DPP IV) and aminopeptidase M (APM). Targeting enzymatic degradation is one approach to prolong endomorphin activity. In this study we characterized the action of two new inhibitors of similar to endomorphins structure, Tyr-Pro-Ala-NH2 (EMDB-2) and Tyr-Pro-Ala-OH (EMDB-3), which were designed earlier in our laboratory. The presented data give evidence that EMDB-2 and EMDB-3 are potent inhibitors of enzymes responsible for endomorphin cleavage. These compounds are stable and easily synthesized. EMDB-2 and EMDB-3 are competitive inhibitors of both, DPP IV and APM, with Ki values in micromolar range. They are less potent than diprotin A in protecting EMs against DPP IV but more potent than actinonin in protecting these peptides against APM.
机译:内啡肽(EMs)是两个内源性μ阿片受体选择性配体,是基于阿片类药物的疼痛管理研究的引人注目的先导化合物。但是,这些肽可被肽酶快速降解,特别是被二肽基肽酶IV(DPP IV)和氨基肽酶M(APM)降解。靶向酶促降解是延长内啡肽活性的一种方法。在这项研究中,我们表征了在实验室中较早设计的两种与内啡肽结构相似的新型抑制剂Tyr-Pro-Ala-NH2(EMDB-2)和Tyr-Pro-Ala-OH(EMDB-3)的作用。 。提出的数据提供了证据,表明EMDB-2和EMDB-3是负责内啡肽裂解的酶的有效抑制剂。这些化合物稳定且易于合成。 EMDB-2和EMDB-3是DPP IV和APM的竞争性抑制剂,Ki值在微摩尔范围内。它们在保护EM对抗DPP IV方面不如双抑肽A强,但在保护这些肽抗AP​​M方面比肌动蛋白更强。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号